The Study
Abstract 1660: Preclinical investigation of orally bioavailable, potent KRASMulti inhibitor JAB-23425
This study tested a new medicine in test tubes and mice, not people. It shows the medicine can stick to cancer proteins and shrink tumors in mice, but we don’t know if it will work in humans.
Analysis score
Maximum 90 for a randomized controlled trial.
Where the score came from
Scientists made a new pill that stops a broken protein (KRAS) that makes many cancers grow, and it works on several different types of this broken protein.
Where does this study sit?
Reviews of RCTs (Meta-analyses)
Max 100Randomized Trials
Max 90Reviews of Cohort Studies
Max 85Cohort Studies
Max 72Reviews of Case-Control Studies
Max 63Case-Control Studies
Max 58Cross-Sectional & Case Series
Max 50Expert Opinion
Max 512 / 100
Quality score
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
Key takeaways
Summary
Based on the study abstract and findings.
- 1Yes — this level of potency suggests the drug could work at very low doses in humans, potentially reducing side effects and helping patients with KRAS mutations who currently have few treatment options.
- 2The pill binds to KRAS mutants with strength less than 1 nanomolar, blocks cancer signals at 1 nM concentration, and kills cancer cells at less than 10 nM — while leaving normal cells and other similar proteins (HRAS/NRAS) alone.
Score breakdown, methodology, conflicts of interest, evidence analysis & raw study data
Publication
Journal
Cancer Research
Year
2023
Authors
P. Wang, Yanping Wang, Xin Sun, Dan Liu, Xiaoyu Liu, Wei Zhang, Xueting He, Rui Zhou, Cunbo Ma, Amin Li, Yiwei Lin, W. Long
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.